This guideline from the Centers for Disease Control and Prevention makes 12 recommendations to improve communication about opioids for chronic pain, to
They expected physician and FDA opioid hesitancy to remain high in that area. But the FDA quickly approved not only the new drug but its descriptive package insert, which included the words “Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability.” That...
Last week, an early sign of the guideline’s impact surfaced in the Senate. Lawmakers there overwhelmingly passed a bill designed to combat opioid abuse, including a provision requiring the Veterans Administration to adopt the CDC recommendations. ___ Medical Writer Mike Stobbe in New York contri...
The U.S. has addressed the opioid crisis using a two-front approach: state regulations limiting opioid prescriptions for acute pain patients, and voluntary federal CDC guidelines on shifting chronic pain patients to lower opioid doses and non-opioids. No opioid policy research to date has ...
They expected physician and FDA opioid hesitancy to remain high in that area. But the FDA quickly approved not only the new drug but its descriptive package insert, which included the words “Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability.” That...
Last week, an early sign of the guideline's impact surfaced in the Senate. Lawmakers there overwhelmingly passed a bill designed to combat opioid abuse, including a provision requiring the Veterans Administration to adopt the CDC recommendations....
The 2022 Clinical Practice Guidelines updates the CDC’s 2016 Guideline for Prescribing Opioids for Chronic Pain in deciding whether to prescribe opioids for pain, the appropriate medication and dosage, duration of the initial prescription, and assessing and addressing the potential harms of opioid use...
Concerns With Statistical Analysis of 2016 CDC Opioid Guideline and Sickle Cell Outcomesdoi:10.1001/jamainternmed.2024.3019Ashwin P. Patel, MBBS, PhDMorgan McLemore, MDVivien A. Sheehan, MD, PhDJAMA internal medicine
The adjusted models estimated that non-opioid pain medication prescribing odds were 2.6% (95%CI: 2.4%-2.8%) higher in the first, 7.7% (95%CI: 7.5%-7.9%) higher in the second, and 8.1% (95%CI: 7.9%-8.3%) higher in the third year post-guideline, than predicted from the pre-...
There was also a significant decrease in the rate of concomitant opioid and benzodiazepine prescribing as well as average days' supply per prescription in the postguideline cohort, as compared with the preguideline cohort.CONCLUSIONS:The average MEDD prescribed in the ED of an academic medical ...